1 |
M. Hu, P. Subramanian, H.I. Mosberg and G.L. Amidon, Use of the peptide carrier system to improve the intestinal absorption of L-a-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-amethyldopa, Pharm. Res., 6, 66-70 (1989)
DOI
|
2 |
D. Jung and A. Dorr, Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects, J. Clin. Pharmacol., 39, 800-4 (1999)
DOI
|
3 |
E-P. Cheon, J.H. Hong and H-K. Han, Enhanced Cellular Uptake of Ara-C via a Peptidomimetic Prodrug, L-Valyl-ara-C in Caco-2 cells, J. Pharm. Pharmacol., 58, 927-932 (2006)
DOI
ScienceOn
|
4 |
P. Wipf and W. Li, Prodrugs of ara-C, Drugs Future, 19, 49- 54 (1994)
|
5 |
P. Wipf, W. Li, C.M. Adeyeye, J.M. Rusnak and J.S. Lazo, Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity, Bioorg. Med. Chem., 4, 1585-96 (1996)
DOI
ScienceOn
|
6 |
P.L. Smith, E.P. Eddy, C.P. Lee and G. Wilson, Exploitation of the intestinal oligopeptide transporter to enhance drug absorption, Drug. Del., 1, 103-111 (1993)
DOI
|
7 |
F.H. Leibach and V. Ganapathy, Peptide transporters in the intestine and the kidney, Annu. Rev. Nutr., 16, 99-119 (1996)
DOI
ScienceOn
|
8 |
S. Weller, M.R. Blum, M. Doucette, T. Burnette, D.M. Cederberg, P. de Miranda and M.L. Smiley, Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers, Clin. Pharmacol. Ther., 54, 595-605 (1993)
DOI
ScienceOn
|
9 |
X. Song, P.L. Lorenzi, C.P. Landowski, B.S. Vig, J.M. Hilfinger and G.L. Amidon, Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport, Mol. Pharm., 2, 157-67 (2005)
DOI
ScienceOn
|
10 |
J.H. Bryan, E.S. Henderson and B.G. Leventhal, Cytosine arabinoside and 6-thioguanine in refractory acute lymphocytic leukemia, Cancer, 33, 539-44 (1974)
DOI
ScienceOn
|
11 |
Y.M. Rustum and R.A. Raymakers, 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview, Pharmacol. Ther., 56, 307-21 (1992)
DOI
ScienceOn
|
12 |
W. Weitschies, D. Cardini, M. Karaus, L. Trahms and W. Semmler, Magnetic marker monitoring of esophageal, gastric and duodenal transit of non-disintegrating capsules, Pharmazie., 54, 426-30 (1999)
|
13 |
S. Grant, Ara-C: cellular and molecular pharmacology, Adv. Cancer Res., 72, 197-233 (1998)
DOI
|
14 |
D.H. Ho and E. Frei, Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine, Clin. Pharmacol. Ther., 12, 944-54 (1971)
DOI
|
15 |
R.B. Greenwald, Y.H. Choe, J. McGuire and C.D. Conover, Effective drug delivery by PEGylated drug conjugates, Adv. Drug Deliv. Rev., 55, 217-50 (2003)
DOI
ScienceOn
|
16 |
A.F. Hadfield and A.C. Sartorelli, The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine, Adv. Pharmacol. Chemother., 20, 21-67 (1984)
DOI
|